Eli Lilly dangles $960M for Rigel's RIPK inhibitor, taking on Sanofi and Denali in neurodegeneration
More than two years after Sanofi and Denali signed their $1 billion neurodegeneration and inflammation pact, they’re getting a deep-pocketed rival.
Eli Lilly announced a partnership Thursday with Rigel to co-develop a set of molecules the biotech developed for inflammatory disorders and neurodegeneration. They’ll pursue the same target as Sanofi and Denali: RIPK1, a signaling protein involved in the same pathway that autoimmune drugs like Humira target. The deal structure is also similar: $125 million upfront, with $835 million in potential milestones.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,900+ biopharma pros reading Endpoints daily — and it's free.